FindTrial
Sign In

Identifying which immune cells are present in blood cancers and how many of each type there are.

Identification and quantification of circulating myeloid derived suppressor cells in myeloid malignancies - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/102270
Enrollment
40
Registered
2026-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

MAULANA AZAD MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: For cases - newly diagnosed cases of myeloid malignancies in male or female patients more that or equal to 18 years of age For control - healthy controls equal to above 18 years of age

Exclusion criteria

Exclusion criteria: For cases - patients on treatment for myeloid malignancies

Design outcomes

Primary

MeasureTime frame
Primary outcome-proportion of circulating MDSCs. In patients of myeloid malignancies by flow cytometry Timepoint: Baseline—

Secondary

MeasureTime frame
Secondary outcome - quantification of circulating PMN -MDSCs ,Mo-MDSCsand e - MDSCs in patients of myeloid malignancies and healthy controls Association of circulating PMN-MDSCs ,Mo-MDSCs and e-MDSCs with clinicopathological parameters in myeloid malignanciesTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Prerna Arora

Maulana Azad Medical College

drprernaarora27@gmail.com09999952113

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026